Endocrine Abstracts

Introduction: Hypercalcemia associated with the use of a SGLT-2 inhibitor is a very rare adverse effect. Herein we reported a case of apparent primary hyperparathyroidism that occurred while applying the treatment of dapagliflozin in a patient with asymptomatic primary hyperparathyroidism.Case report: A 49-year-old male patient with 5 years of diabetes mellitus history admitted for his routine control and Hba1c level was observed 7.9%. Dapagliflozin (1 &...